Patent intelligence · US
US 7582307
Dermatological composition
Dermatological composition
Patent details — US 7582307
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 1, 2009
- Expiration
- Aug 27, 2029
- Applicant
- Harmony Labs, Inc.
- Claims
- 5
- CPC classes
- A61K, A61K36/185, A61K36/28, A61K36/48
Quick answer
US 7582307 (Dermatological composition) is held by Harmony Labs, Inc.. Status: granted. Granted Sep 1, 2009. Expires Aug 27, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Harmony Labs, Inc.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K36/185, A61K36/28, A61K36/48, A61K8/922, A61P
More from Harmony Labs, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12226373
Treatment of fragile X syndrome with cannabidiol
granted -
US 12213951
Treatment of autism with cannabidiol
granted -
US 12186282
Treatment of 22Q11.2 deletion syndrome with cannabidiol
granted -
US 9296774
Halogenated dideoxy sugar derivates, preparation method and application thereof
granted -
US 7625575
Dermatological composition
granted
Frequently asked questions
What is US patent 7582307?
US 7582307 (Dermatological composition) is held by Harmony Labs, Inc.. Status: granted. Granted Sep 1, 2009. Expires Aug 27, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7582307?
Harmony Labs, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 7582307 expire?
Our index shows an expiration date of Aug 27, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.